CapsoVision, Inc. (CV)

CapsoVision, Inc. had its Initial Public Offering (IPO) on July 2, 2025, with an initial public offering price of $5.00 per share. Its common stock was approved for listing on the Nasdaq Capital Market under the symbol "CV".

The provided search results do not contain specific information regarding the demand seasonality for CapsoVision, Inc.'s products and services.

CapsoVision, Inc. is a medical technology company specializing in capsule endoscopy systems for gastrointestinal diagnostics, manufacturing and marketing endoscopic video imaging devices. Its major products include the CapsoCam Plus, a capsule endoscopy system for small bowel visualization, CapsoCam Colon for colon visualization and polyp detection, and CapsoColon 3D for the large intestines. The company also provides a cloud-based software-as-a-service ecosystem called CapsoCloud, CapsoAccess, CapsoView, and CapsoRetrieve. CapsoVision serves gastrointestinal medical practices, clinics, and hospitals, selling its products through distributors.

CapsoVision, Inc. is headquartered in Saratoga, California, United States. The company's supply chain involves suppliers located in Asia, particularly Taiwan and Japan. The company sells its products through distributors.

The company highlights positive feedback from users regarding its CapsoCam Plus system, with users stating it's a "huge improvement in technology" offering a "much better perspective" and a "much better chance of picking up on small lesions", and that the "wider camera lens and giving a more all encompassing look at the small intestine."

As of the IPO on July 2, 2025, 36 existing stockholders and 41 additional investors agreed to purchase shares totaling approximately $18.9 million, representing about 69% of the shares sold in the offering. These introduced investors were not company directors, officers, or 5% stockholders, and none would beneficially own more than 5% of the outstanding shares after the offering.